APSR2026-1019

 
Late-Breaking
Submitted
Poster Presentation
 
AP12-021
P98
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1245029-46904-APSR2026_IP_Prognosis_Final_v10_434221.pdf
Format: PDF Only
16. Interstitial Lung Disease
7

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Hiroaki Harada * NHO Higashihiroshima Medical Center Thoracic Surgery Higashihiroshima Japan
Toru Arai - NHO Kinki Chuo Chest Medical Center Respiratory Medicine Sakai Japan
Yukiyasu Takeuchi - NHO Osaka Toneyama Medical Center Thoracic Surgery Toyonaka Japan
Takehiro Watanabe - NHO Nishiniigata Chuo Hospital Thoracic Surgery Niigata Japan
Kazushi Doshita - NHO Asahikawa Medical Center Respiratory Medicine Asahikawa Japan
Riki Okita - NHO Yamaguchi Ube Medical Center Thoracic Surgery Ube Japan
Kazuyoshi Inoue - NHO Kinki Chuo Chest Medical Center Respiratory Medicine Sakai Japan
 
 
 
 
 
 
 
 
Presenting Author Details
Hiroaki
Harada
Hhiroaki0512@gmail.com
+819052866655
51-60
Japan
Original Research
30-, 90-, and 180-Day Post-Treatment Outcome and Prognosis in Cases of Pneumothorax Complicated by Interstitial Lung Disease
Maximum 25 words
Abstract Content
Secondary spontaneous pneumothorax (SSP) complicated by interstitial lung disease (ILD) is often difficult to treat. A prospective real-world data study was conducted at 30 institutions in Japan involving 191 cases of SSP complicated by IP.Secondary spontaneous pneumothorax (SSP) complicated by interstitial lung disease (ILD) is often difficult to treat. A prospective real-world data study was conducted at 30 institutions in Japan involving 191 cases of SSP complicated by ILD.
We recently collected and evaluated data on survival rates and recurrence rates at 30, 90, and 180 days following various treatments (including drainage alone, surgery, pleural sclerosis, and bronchial occlusion) for these 191 cases.
Although this study included only cases in which the attending physician judged that a prognosis of at least 30 days could be expected after the start of treatment, 15 patients died within 30 days of treatment initiation (9 due to interstitial pneumonia). Twenty-five patients remained hospitalized due to persistent pneumothorax, and 10 patients experienced a recurrence within 30 days despite initial improvement. An additional 33 patients died between 31 and 90 days after treatment initiation (16 due to interstitial pneumonia); of these, 15 had resolved pneumothorax but died, and 9 had not undergone drainage. Pneumothorax recurred in 14 patients between 31 and 90 days after treatment initiation. An additional 20 patients died between 91 and 180 days after the start of treatment (7 due to interstitial pneumonia); of these, 13 died despite resolution of the pneumothorax, and 6 had not undergone drainage. There were 10 patients in whom the pneumothorax recurred between 91 and 180 days after the start of treatment, despite having initially resolved.
The recurrence rate of pneumothorax is high in ILD-related SSP. Furthermore, it is noteworthy that 68 of the 191 cases of ILD-associated SSP (35.6%) died within 180 days of treatment initiation. This indicates that the prognosis for this disease is extremely poor.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Secondary Pneumothorax, Interstitial Pneumonia, Prognosis
maximum 3 keywords and no abbreviations, separated by commas
 
312